UY35014A - Moduladores heterocíclicos de los receptores de hormonas nucleares - Google Patents
Moduladores heterocíclicos de los receptores de hormonas nuclearesInfo
- Publication number
- UY35014A UY35014A UY0001035014A UY35014A UY35014A UY 35014 A UY35014 A UY 35014A UY 0001035014 A UY0001035014 A UY 0001035014A UY 35014 A UY35014 A UY 35014A UY 35014 A UY35014 A UY 35014A
- Authority
- UY
- Uruguay
- Prior art keywords
- hormone receptors
- nuclear hormone
- heterocyclic modulators
- modulators
- heterocyclic
- Prior art date
Links
- 102000007399 Nuclear hormone receptor Human genes 0.000 title 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000001900 immune effect Effects 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 230000000771 oncological effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
- C07F9/65038—Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un compuesto de fórmula (I) sales, prodrogas, metabolitos biológicamente activos, estereoisómeros e isómeros farmacéuticamente aceptables del mismo, en donde las variables se definieron en la presente. Los compuestos de la invención son de utilidad para el tratamiento de condiciones inmunológicas y oncológicas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261698221P | 2012-09-07 | 2012-09-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY35014A true UY35014A (es) | 2014-03-31 |
Family
ID=50237618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001035014A UY35014A (es) | 2012-09-07 | 2013-09-06 | Moduladores heterocíclicos de los receptores de hormonas nucleares |
Country Status (6)
Country | Link |
---|---|
US (1) | US9193744B2 (es) |
EP (1) | EP2892527A4 (es) |
AR (1) | AR092474A1 (es) |
TW (1) | TW201422590A (es) |
UY (1) | UY35014A (es) |
WO (1) | WO2014039757A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2935284A4 (en) | 2012-12-21 | 2016-04-27 | Abbvie Inc | HETEROCYCLIC MODULATORS OF HORMONE NUCLEAR RECEPTORS |
US9643947B2 (en) | 2013-08-28 | 2017-05-09 | Northwestern University | 7-membered fused heterocycles and methods of their synthesis |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2111138A1 (en) | 1993-01-15 | 1994-07-16 | Thierry Godel | Octahydrophenanthrene derivatives |
CA2176722A1 (en) | 1993-12-28 | 1995-07-06 | Ruth E. Ten Brink | Heterocyclic compounds for the treatment of cns and cardiovascular disorders |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
EP1070046A1 (en) | 1998-04-06 | 2001-01-24 | Fujisawa Pharmaceutical Co., Ltd. | Propanolamine derivatives |
PT1119543E (pt) | 1998-10-07 | 2005-03-31 | Ortho Mcneil Pharm Inc | N-aralquilaminotetralinas como ligandos para o receptor y5 do neuropeptido y |
OA11877A (en) | 1999-04-30 | 2006-03-29 | Pfizer Prod Inc | Glucocorticoid receptor modulators. |
IL139197A0 (en) | 1999-10-29 | 2001-11-25 | Pfizer Prod Inc | Use of corticotropin releasing factor antagonists and related compositions |
US7713989B2 (en) | 2000-04-27 | 2010-05-11 | Dow Robert L | Glucocorticoid receptor modulators |
US6653471B2 (en) | 2000-08-07 | 2003-11-25 | Neurogen Corporation | Heterocyclic compounds as ligands of the GABAA receptor |
IL180679A0 (en) | 2000-10-27 | 2009-02-11 | Pfizer Prod Inc | Process for the preparation of non-steroidal glucocorticoid receptor modulators |
ES2262612T3 (es) | 2000-10-28 | 2006-12-01 | Pfizer Products Inc. | Moduladpres del receptor de glucocorticoides. |
ATE303369T1 (de) | 2000-10-30 | 2005-09-15 | Pfizer Prod Inc | Glucocorticoid rezeptor modulatoren |
EP1496892B1 (en) * | 2002-04-11 | 2011-01-26 | Merck Sharp & Dohme Corp. | 1h-benzo(f)indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
US20030224349A1 (en) | 2002-05-31 | 2003-12-04 | Pfizer Inc. | Rapid assay to assess the potential for glucocorticoid analogs to promote the differentiation of human osteoblasts and predict bone safety |
TW200400816A (en) | 2002-06-26 | 2004-01-16 | Lilly Co Eli | Tricyclic steroid hormone nuclear receptor modulators |
DK1521733T3 (da) | 2002-07-08 | 2014-10-13 | Pfizer Prod Inc | Modulatorer af glucocorticoid receptoren |
JP4520309B2 (ja) * | 2002-09-20 | 2010-08-04 | メルク・シャープ・エンド・ドーム・コーポレイション | 選択的糖質コルチコイド受容体調節剤としてのオクタヒドロ−2−H−ナフト[1,2−f]インドール−4−カルボキサミド誘導体 |
JP4648303B2 (ja) | 2003-02-25 | 2011-03-09 | メルク・シャープ・エンド・ドーム・コーポレイション | 選択的非ステロイド系糖質コルチコイド受容体調節剤 |
US7781591B2 (en) | 2006-06-13 | 2010-08-24 | Wyeth Llc | Substituted 3-cyanopyridines as protein kinase inhibitors |
JP2007511501A (ja) | 2003-11-13 | 2007-05-10 | ファイザー・プロダクツ・インク | グルココルチコイド受容体調節剤として有用なオクタヒドロフェナンスレンヒドラジド誘導体 |
CN101060838B (zh) * | 2004-09-20 | 2012-02-29 | 詹森药业有限公司 | 用作类固醇性激素受体调节剂的新的含杂原子的四环衍生物 |
US20060247266A1 (en) | 2004-11-26 | 2006-11-02 | Asahi Kasei Pharma Corporation | Nitrogen-containing tricyclic compounds |
WO2006081659A1 (en) | 2005-02-01 | 2006-08-10 | The University Of British Columbia | Meroterpenoid inhibitors of phosphoinositide 3 kinase (pi3k) |
WO2006108699A1 (en) | 2005-04-14 | 2006-10-19 | Glaxo Group Limited | Indazoles as glucocorticoid receptor ligands |
JP4873614B2 (ja) | 2006-01-16 | 2012-02-08 | 国立大学法人 東京大学 | カリウムチャネル開口薬 |
US8067447B2 (en) | 2006-11-01 | 2011-11-29 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
RS51970B (en) | 2007-02-02 | 2012-02-29 | Pfizer Products Inc. | TRICYCLIC UNITS AND THEIR USE AS MODULATORS OF GLUCOCORTICOID RECEPTORS |
UZ4378C (en) | 2007-02-02 | 2011-07-29 | Pfizer Prod Inc | Tricyclic compounds and their use as glucocorticoid receptor modulators |
EA201070535A1 (ru) | 2007-11-30 | 2010-12-30 | Пфайзер Лимитед | Новые агонисты глюкокортикоидных рецепторов |
JP2009209068A (ja) | 2008-03-03 | 2009-09-17 | Univ Of Tokyo | カリウムチャネル開口薬 |
SI2300472T1 (sl) | 2008-06-06 | 2012-05-31 | Boehringer Ingelheim Int | Glukokortikoidni mimetiki postopki za njihovo pripravo farmacevtski sestavki in njihove uporabe |
AP2744A (en) | 2008-07-28 | 2013-09-30 | Pfizer | Phenanthrenone compounds, compositions and methods |
WO2010040527A1 (en) | 2008-10-10 | 2010-04-15 | Priaxon Ag | Novel compounds which modulate kinase activity |
EP2435462A1 (en) | 2009-05-29 | 2012-04-04 | Pfizer Limited | Novel glucocorticoid receptor agonists |
WO2011081173A1 (ja) * | 2009-12-29 | 2011-07-07 | 協和発酵キリン株式会社 | 四環系化合物 |
CN102584860B (zh) | 2011-01-17 | 2014-12-10 | 苏州大学 | 含吲哚结构的螺杂环化合物及其制备方法 |
JP2014509592A (ja) | 2011-03-15 | 2014-04-21 | アッヴィ・インコーポレイテッド | 核ホルモン受容体モジュレーター |
CA2844730A1 (en) | 2011-09-01 | 2013-03-07 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine kinase inhibitors |
EP2935284A4 (en) | 2012-12-21 | 2016-04-27 | Abbvie Inc | HETEROCYCLIC MODULATORS OF HORMONE NUCLEAR RECEPTORS |
-
2013
- 2013-09-03 TW TW102131642A patent/TW201422590A/zh unknown
- 2013-09-06 UY UY0001035014A patent/UY35014A/es not_active Application Discontinuation
- 2013-09-06 EP EP13835365.1A patent/EP2892527A4/en not_active Withdrawn
- 2013-09-06 US US14/019,980 patent/US9193744B2/en active Active
- 2013-09-06 WO PCT/US2013/058397 patent/WO2014039757A1/en active Search and Examination
- 2013-09-06 AR ARP130103182A patent/AR092474A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP2892527A1 (en) | 2015-07-15 |
US9193744B2 (en) | 2015-11-24 |
WO2014039757A1 (en) | 2014-03-13 |
AR092474A1 (es) | 2015-04-22 |
EP2892527A4 (en) | 2016-01-27 |
TW201422590A (zh) | 2014-06-16 |
US20140162985A1 (en) | 2014-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20130500A (es) | Moduladores de los receptores de hormonas nucleares | |
UY35630A (es) | Carboxamidas primarias como inhibidores de btk | |
CR20160007A (es) | Nuevos compuestos triciclicos | |
CO6561771A2 (es) | Nuevos compuestos triciclicos | |
ECSP12011968A (es) | Nuevos compuestos tricíclicos | |
CU24605B1 (es) | Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2 | |
UY35818A (es) | Composiciones y métodos para modular los receptores x farnesoides | |
CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
GT201300174A (es) | Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme) | |
UY35663A (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
BR112016024057A2 (pt) | inibidores de quinases heterocíclicos | |
UY36629A (es) | Indazolonas como moduladores de la señalización de tnf | |
UY36170A (es) | Compuestos de dihidroisoquinolinona sustituida | |
ECSP15025947A (es) | Derivados de cloro-pirazin carboxamida con actividad bloqueadora sobre los canales de sodio epiteliales | |
CU20130139A7 (es) | Derivados glocósidos y usos de los mismos | |
ECSP13013026A (es) | Isoxazolinas como agentes terapéuticos | |
UY36630A (es) | Moduladores tricíclicos de la señalización por tnf | |
CO2017012594A2 (es) | Moduladores de receptor nuclear | |
CR20140508A (es) | Moduladores de la ruta del complemento y usos de los mismos | |
UY36628A (es) | Indazolonas como moduladores de la señalización de tnf | |
UY35223A (es) | Moduladores heterocíclicos de receptores de hormonas nucleares | |
GT201400167A (es) | Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2 | |
UY35014A (es) | Moduladores heterocíclicos de los receptores de hormonas nucleares | |
CU20140127A7 (es) | Moduladores de la ruta del complemento y usos de los mismos | |
CO7141426A2 (es) | Moduladores de la ruta del complemento y usos de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20210609 |